BiBBInstruments AB
Press release, November 24, 2026

Scheeletorget 1
Medicon Village
SE-223 81 Lund
www.bibbinstruments.com

BiBBInstruments Receives New Order for EndoDrill® GI from the US

BiBBInstruments AB ("BiBB" or the "Company"), developer of EndoDrill® – the world's first market-cleared powered biopsy instrument for endoscopy – today announces that the Company has received a new order from its US distribution partner TaeWoong Medical USA valued at approximately SEK 1.2 million (USD 118,140). Delivery and invoicing are planned for the first quarter of 2027.

The new order is in addition to the orders valued at approximately SEK 1.75 million announced by BiBB on September 22, 2026. A portion of these previous orders is now expected to be delivered and invoiced in the first quarter of 2027 rather than in the fourth quarter of 2026.

"The new order further confirms our US partner's confidence in EndoDrill® GI. Over the coming months, TaeWoong Medical USA will strengthen its commercial organization, creating favorable conditions for sales growth in the US market," says Fredrik Lindblad, CEO of BiBB.

About EndoDrill® GI

EndoDrill® GI is the world's first market-cleared powered biopsy instrument for endoscopic ultrasound (EUS), with both FDA 510(k) clearance and CE marking. Unlike conventional manual biopsy needles, EndoDrill® uses a powered rotating needle tip designed to obtain intact cores for histopathological and molecular analysis. The system is currently being commercialized in the US through distribution partner TaeWoong Medical USA. The European commercial launch began in Spain in the fall of 2026 through distribution partner Palex Medical Spain, marking the first step in BiBB's planned expansion in Europe.

For more information about BiBB, please contact:

Fredrik Lindblad, CEO
Email: fredrik.lindblad@bibbinstruments.com
Phone: +46 70 899 94 86
www.bibbinstruments.com

This information is information that BiBBInstruments AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU) No. 596/2014. The information was submitted for publication, through the agency of the contact person set out above, at the time specified by the Company's news distributor in connection with the publication of this press release.

About BiBBInstruments AB

BiBBInstruments AB is a cancer diagnostics company that develops and manufactures EndoDrill®, the world's first product family of market-cleared powered biopsy instruments for endoscopy. EndoDrill® enables the collection of intact tissue cores for histopathological and molecular analysis, aiming to improve cancer diagnostics. The product portfolio comprises EndoDrill® GI, EndoDrill® EBUS and EndoDrill® URO, all of which are CE-marked under the EU MDR, while EndoDrill® GI also has FDA 510(k) clearance. Commercialization of EndoDrill® GI is underway in the US and Europe through distribution partners. BiBB is headquartered at Medicon Village in Lund, Sweden, and is listed on Spotlight Stock Market (ticker: BIBB).